Tuparstobart is under clinical development by Incyte and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase II drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tuparstobart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tuparstobart overview
Tuparstobart (INCAGN-2385) is under development for the treatment of solid tumors, melanoma, colon carcinoma, cervical cancer, endometrial cancer, gastric cancer, gastroesophageal (GE) junction carcinomas, esophageal cancer, metastatic hepatocellular carcinoma, metastatic melanoma, merkel cell carcinoma, malignant mesothelioma, metastatic colorectal cancer, non-small cell lung cancer, metastatic ovarian cancer, small-cell lung cancer, triple-negative breast cancer, transitional cell carcinoma, recurrent and metastatic squamous cell carcinoma of the head and neck including oropharyngeal cancer, oral cavity cancer, hypopharynx cancer, and laryngeal cancer and head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The therapeutic candidate is checkpoint modulator antibody acts by antagonizing the lymphocyte-activation gene 3 (LAG-3). The therapeutic candidate is developed based on the retrocyte display technology. It was under development for the treatment of diffuse large B-cell lymphoma.
Incyte overview
Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
For a complete picture of Tuparstobart’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
